Search
4D Molecular Therapeutics Inc
FDMTAdd to Watchlist
13.670USD
-0.170-1.23%
Close 10-02 16:00（ET）
714.67MMarket Cap
LossP/E TTM
4D Molecular Therapeutics Inc (FDMT) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to 4D Molecular Therapeutics Inc in the past month.
Buy
3 Strong Buy
8 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
28.182USD+106.16%
FDMT Analyst Recommendation Trends
In the current month, FDMT has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. FDMT average Analyst price target in the last month is 28.182.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
8
8
7
6
6
6
6
6
1
1
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
11
11
11
11
11
FDMT Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, FDMT EPS is projected to reach -1.050 in FY2026Q3, following reported EPS of -1.038 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.76
-0.99
-1.02
-1.05
-1.05
Actual
0.30
-1.01
-1.04
--
--
Surprise
+139.80%
-1.81%
-2.09%
--
--
FAQs
What is 4D Molecular Therapeutics Inc's expected revenue for the next quarter?
4D Molecular Therapeutics Inc's expected revenue is 2.54M.
What is 4D Molecular Therapeutics Inc's price target?
Analysts forecast that 4D Molecular Therapeutics Inc's price target is USD 28.18, with the highest forecast at USD 37.00 and the lowest forecast at USD 18.00.
How have 4D Molecular Therapeutics IncFDMT's recent earnings per share performed?
The market expectation was USD -1.04, while 4D Molecular Therapeutics IncFDMT's earnings per share (EPS) for the previous quarter was USD -1.01. EPS for the next quarter is expected at USD -1.05.
What is the analyst rating for 4D Molecular Therapeutics Inc?
Based on the ratings of 4D Molecular Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.